文献速递胸部技术与安全PETCT

非小细胞肺癌切除标本中18F-FDG代谢活性与程序性死亡配体-1(PD-L1)表达(22C3免疫组化检测)的关联

Association between 18F-FDG metabolic activity and programmed death ligand-1 (PD-L1) expression using 22C3 immunohistochemistry assays in non-small cell lung cancer (NSCLC) resection specimens.
PubMed 文献 · Br J Radiol · 2021-01-25

该回顾性研究纳入2017年10月至2019年12月419例连续接受18F-FDG PET/CT及PD-L1 22C3检测的非小细胞肺癌患者,分析代谢活性与PD-L1表达的关联。结果显示PD-L1阳性率为38.2%(160/419),多因素分析中高SUVmax(p<0.0001)和EGFR野生型(p=0.027)与PD-L1阳性显著相关;NSCLC和腺癌中SUVmax的AUC分别为0.767和0.712。作者认为SUVmax作为代谢生物标志物可能有助于筛选可能从帕博利珠单抗获益的NSCLC患者。

要点

  • NSCLC中PD-L1阳性率为38.2%(160/419),高SUVmax与PD-L1阳性显著相关(p<0.0001)。
  • NSCLC中SUVmax预测PD-L1阳性的AUC为0.767(95%CI 0.720-0.814),腺癌中为0.712(95%CI 0.651-0.774)。
  • EGFR野生型与PD-L1阳性显著相关(p=0.027),腺癌中仅高SUVmax与PD-L1阳性显著相关(p<0.0001)。

核心结论

  • SUVmax与NSCLC及腺癌的PD-L1表达显著相关,PD-L1高表达与低表达组间SUVmax差异有统计学意义(NSCLC p=0.011,腺癌 p=0.013)。
  • 作者认为SUVmax作为代谢生物标志物可能有助于筛选可能从帕博利珠单抗获益的NSCLC患者。

研究设计与样本

  • 回顾性研究,2017年10月至2019年12月连续纳入419例非小细胞肺癌患者,均接受18F-FDG PET/CT扫描及PD-L1 22C3免疫组化检测。
  • 分析临床病理特征与PD-L1表达的关联,采用多因素分析、Mann-Whitney U检验及ROC曲线分析。

诊断标准与关键数值

  • PD-L1阳性定义为22C3检测PD-L1表达阳性,NSCLC中阳性频率为38.2%(160/419)。
  • NSCLC中SUVmax预测PD-L1阳性的AUC为0.767(95%CI 0.720-0.814;p<0.0001)。
  • 腺癌中SUVmax预测PD-L1阳性的AUC为0.712(95%CI 0.651-0.774;p<0.0001)。

临床应用与阅片要点

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

OBJECTIVE: This study sought to investigate the association between 18F-fludeoxyglucose (18F-FDG) uptake in positron emission tomography/CT (PET/CT) scans and different programmed death ligand-1 (PD-L1) expression conditions in non-small cell lung cancer (NSCLC).

METHODS: From October 2017 to December 2019, NSCLC was retrospectively identified in 419 consecutive patients who underwent 18F-FDG PET/CT scans and PD-L1 expression tests using the PD-L1 22C3 assay. The association between clinicopathological characteristics and PD-L1 expression was assessed.

RESULTS: The frequency of PD-L1-positive tumours was 38.2% (160/419) in NSCLC. In NSCLC, the multivariate analysis showed a high maximum standardised uptake value (SUVmax) (p < 0.0001) and an EGFR wild type genotype (p = 0.027) was significantly associated with PD-L1-positivity. In adenocarcinoma (ADC), the multivariate analysis showed that a high SUVmax (p < 0.0001) was significantly associated with PD-L1-positivity. In NSCLC and ADC, a Mann-Whitney U test showed significant differences between groups with PD-L1 high expression and PD-L1 low expression levels in terms of SUVmax (p = 0.011 and p = 0.013, respectively). The results of the receiver operating characteristic curve analysis showed that the area under the curve of the SUVmax was 0.767 (95% CI, 0.720-0.814; p < 0.0001) and 0.712 (95% CI, 0.651-0.774; p < 0.0001) in NSCLC and ADC, respectively.

CONCLUSION: The study demonstrates that the SUVmax was significantly associated with PD-L1 expression in NSCLC and ADC. The SUVmax was significantly different between the PD-L1 high and low expression conditions, as quantified using a PD-L1 22C3 assay.

ADVANCES IN KNOWLEDGE: This study provides direct evidence that SUVmax as a metabolic biomarker may help select patients with NSCLC likely to benefit from pembrolizumab.

来源:Br J Radiol,查看原文。版权归原作者所有。

引用

  1. Zhao L, Liu J, Wang H, et al. Association between 18F-FDG metabolic activity and programmed death ligand-1 (PD-L1) expression using 22C3 immunohistochemistry assays in non-small cell lung cancer (NSCLC) resection specimens. Br J Radiol. 2021. PMID: 33492995. doi:10.1259/bjr.20200397

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。